Pancreatic Cancer Research

ResearcherUniversity of GroningenNo recent work listed

Ingrid C. A. W. Konings

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9027-0570; OpenAlex author ID A5035628966. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers

Papers 11

  1. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  2. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Co-author DOI 10.1136/gutjnl-2020-323611↗
  3. Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. Co-author DOI 10.1002/ijc.33540↗
  4. Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-020-00171-8↗
  5. Surveillance for pancreatic cancer in high-risk individuals. Co-author DOI 10.1002/bjs5.50180↗
  6. Evolution of features of chronic pancreatitis during endoscopic ultrasound-based surveillance of individuals at high risk for pancreatic cancer. Co-author DOI 10.1055/a-0574-2396↗
  7. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance. Co-author DOI 10.1007/s10689-016-9930-4↗
  8. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000725↗
  9. Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Co-author DOI 10.1002/pon.4047↗
  10. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. First author DOI 10.1136/gutjnl-2014-308008↗
  11. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study. Co-author DOI 10.1186/s13104-015-1235-4↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeanin Elise van Hooft · 10 shared papers, 2016–2022 · strength 0.81
  2. Marco J. Bruno · 10 shared papers, 2016–2022 · strength 0.81
  3. Femme Harinck · 9 shared papers, 2016–2022 · strength 0.70
  4. Djuna L. Cahen · 5 shared papers, 2018–2022 · strength 0.52
  5. Brechtje D.M. Koopmann · 3 shared papers, 2021–2022 · strength 0.34
  6. Kasper A. Overbeek · 3 shared papers, 2020–2022 · strength 0.31
  7. Casper H.J. van Eijck · 3 shared papers, 2016–2022 · strength 0.25
  8. Iris J. M. Levink · 2 shared papers, 2022 · strength 0.22
  9. Bas Groot Koerkamp · 2 shared papers, 2020–2022 · strength 0.21
  10. Marc G. Besselink · 2 shared papers, 2020–2022 · strength 0.21
  11. Eveline M. A. Bleiker · 3 shared papers, 2016–2020 · strength 0.20
  12. Jesse Lachter · 2 shared papers, 2019–2022 · strength 0.18
  13. Marcia Irene Canto · 2 shared papers, 2019–2022 · strength 0.18
  14. Randall E. Brand · 2 shared papers, 2019–2022 · strength 0.18
  15. Michael Goggins · 2 shared papers, 2019–2022 · strength 0.18
  16. Sapna Syngal · 2 shared papers, 2019–2022 · strength 0.18
  17. Aimee Lee Lucas · 2 shared papers, 2019–2022 · strength 0.18
  18. Salvatore Paiella · 2 shared papers, 2019–2022 · strength 0.18
  19. Elena M. Stoffel · 2 shared papers, 2019–2022 · strength 0.18
  20. Fay Kastrinos · 2 shared papers, 2019–2022 · strength 0.18
  21. Inge M.C.M. de Kok · 1 shared paper, 2021 · strength 0.12
  22. Lydi M.J.W. van Driel · 1 shared paper, 2022 · strength 0.12
  23. Detlef Klaus Bartsch · 1 shared paper, 2022 · strength 0.10
  24. Elizabeth Half · 1 shared paper, 2022 · strength 0.10
  25. Alfredo Carrato Mena · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.